INS and type 2 diabetes mellitus: In a selected population of individuals with type 2 diabetes on insulin therapy, this study confirmed that the addition of a GLP-1 RA (liraglutide, semaglutide, or dulaglutide) effectively reduced HbA1C, body weight, and insulin requirements.